



IARC Handbooks of Cancer Prevention
Volume 21: Lung Cancer Screening
17 November–3 December 2025 (remote)
and
20–24 April 2026 (in person)
IARC, Lyon, France

LIST OF PARTICIPANTS

Working Group Members and Invited Specialists served in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only.

Members

Ali Saeed Al-Zahrani, King Faisal Specialist Hospital and Research Centre, Saudi Arabia
Zhandos Amankulov, Kazakh Institute of Oncology and Radiology, Kazakhstan
Jean-Luc Bulliard, Center for Primary Care and Public Health (Unisanté), Switzerland
Matthew Callister, St James's University Hospital, United Kingdom (*Subgroup Chair, Screening*)
Wendy Cooper, Royal Prince Alfred Hospital, Australia
Luis Corrales, Centro de Investigación y Manejo del Cáncer (CIMCA), Costa Rica¹
Philip Crosbie, University of Manchester, United Kingdom (*Subgroup Chair, Delivery*)
Harry De Koning, Erasmus Medical Center, The Netherlands (*Overall Chair*)
Neal Freedman, National Cancer Institute, USA [withdrew]
Paolo Giorgi Rossi, AUSL-IRCCS di Reggio Emilia, Italy
Rayjean Hung, Lunenfeld-Tanenbaum Research Institute of the Sinai Health System, Canada
Ella Kazerooni, University of Michigan, USA
Stephen Lam, BC Cancer and University of British Columbia, Canada (*Subgroup Chair, Emerging*)
MengMeng Li, Sun Yat-sen University Cancer Center, China
Rafael Meza, BC Cancer Research Institute, Canada
Arn Migowski, National Cancer Institute (INCA), Brazil²
Vivienne Milch, Cancer Australia, Australia (*Subgroup Chair, Epidemiology*)
Rachael Murray, University of Nottingham, United Kingdom
Samantha Quaife, Wolfson Institute of Population Health, Queen Mary University of London, United Kingdom
Robert Rintoul, University of Cambridge, United Kingdom
Witold Rzyman, University Hospital of the Medical University of Gdańsk, Poland³
Wei Jie Seow, Saw Swee Hock School of Public Health, National University of Singapore, Singapore
Abhishek Shankar, All India Institute of Medical Sciences Delhi, India

¹ Luis Corrales reports that he is a member of the Latin American Consortium for Lung Cancer Research (CLICaP), which receives research funding from AstraZeneca for a Latin American lung cancer screening study in four countries. The study is designed, conducted, and analysed independently by CLICaP, and AstraZeneca has no role in study governance or reporting.

² Arn Migowski reports that his unit at INCA Brazil receives research funding from AstraZeneca for a project on the implementation of lung cancer screening. This was determined not to present a conflict of interest for the present *IARC Handbooks* meeting, since the expert receives no personal or institutional benefit from this grant and the funding is managed independently through an external foundation, with no involvement of AstraZeneca in the study design, conduct, or interpretation of results.

³ Witold Rzyman reports having served as an advisory board member for AstraZeneca. This involvement was specific to a project that concluded 2 years ago, with no ongoing ties or current involvement. This was determined not to present a conflict of interest restricting his participation at this meeting.



Invited Specialist

Peter Mazzone, Cleveland Clinic, USA⁴

Representatives

Greta Castellini, European Commission Directorate-General Joint Research Centre (JRC), Ispra, Italy

Maxime Rigaud, French National Cancer Institute (INCa), Boulogne-Billancourt, France

Yannick Romero, Union for International Cancer Control (UICC), Geneva, Switzerland

Observers

Chisato Hamashima, Teikyo University, Tokyo, Japan

Sebastian Schmidt, Siemens Healthineers AG, Forchheim, Germany

Lucía Viola, Fundación Neumológica Colombiana – Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center, Bogotá, Colombia

Helena Wilcox, Lung Cancer Policy Network, London, United Kingdom

IARC/WHO Secretariat

Maribel Almonte Pacheco, WHO headquarters

Roya Dolatkah, Environment and Lifestyle Epidemiology Branch

V. Paul Doria-Rose, Evidence Synthesis and Classification Branch [withdrew]

Thaís Esteves Pereira, Early Detection, Prevention, and Infections Branch

Xiaoshuang Feng, Early Detection, Prevention, and Infections Branch

Mattias Johansson, Early Detection, Prevention, and Infections Branch

Ravivarman Lakshmanasamy, Early Detection, Prevention, and Infections Branch

Béatrice Lauby-Secretan, Head of the *IARC Handbooks* Programme, Deputy Head of the Evidence Synthesis and Classification Branch

Daniela Mariosa, Evidence Synthesis and Classification Branch

Karen Müller, Services to Science and Research Branch (*Editor*)

Luciana Neamtiu, Evidence Synthesis and Classification Branch (*Responsible Officer*)

David Ritchie, Early Detection, Prevention, and Infections Branch

Hilary Robbins, Early Detection, Prevention, and Infections Branch

Mahdi Sheikh, Early Detection, Prevention, and Infections Branch

Kayo Togawa, Early Detection, Prevention, and Infections Branch

NOTE REGARDING CONFLICTS OF INTERESTS:

Working Group Members and Invited Specialists served in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only.

Invited Specialists did not serve as Meeting Chair or Subgroup Chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations.

Each participant was asked to declare potentially relevant research, employment, and financial interests that are current or that have occurred during the past 4 years. Minimal interests are not disclosed here, and include stock valued at no more than US\$ 1000 overall, grants that provide no more than 5% of the research budget of the expert's organization and that do not

⁴ Peter Mazzone reports that his unit at Cleveland Clinic benefits from research funding from Adela, Biondesix, DELFI, Nucleix, Veracyte, and the Patient-Centered Outcomes Research Institute (PCORI) (current) and from Exact Sciences and the Moore Foundation (past), and being editor in chief of the *CHEST* journal.



support the expert's research or position, and consulting or speaking on matters not before a court or government agency that does not exceed 2% of total professional time or compensation. All other non-publicly funded grants that support the expert's research or position and all consulting or speaking on behalf of an interested party on matters before a court or government agency are disclosed as potentially significant conflicts of interests.

NOTE REGARDING OBSERVERS:

Each Observer agreed to respect the Guidelines for Observers at *IARC Handbooks* meetings. The Observers did not serve as Meeting Chair or Subgroup Chair, draft any part of the *Handbook*, or participate in the evaluations. They also agreed not to contact participants before the meeting, not to lobby them at any time, not to send them written materials, and not to offer them meals or other favours. IARC asked and reminded Working Group Members to report any contact or attempt to influence that they may have encountered, either before or during the meeting.

Posted on 17 September 2025, updated on 27 April 2026